Nektar Therapeutics vs Nuvation Bio
Nuvation Bio reported revenue of $63 million in fiscal 2025, about the same as Nektar Therapeutics' $55 million in fiscal 2025. Nektar Therapeutics' revenue fell 43.9% in its latest year, and Nuvation Bio's grew 699.0%. Nektar Therapeutics had an operating margin of -253.7%, against -338.7% at Nuvation Bio. Free cash flow was −$209 million at Nektar Therapeutics and −$181 million at Nuvation Bio.
Side by side
| Nektar Therapeutics | Nuvation Bio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $55M | $63M |
| Revenue growth | −43.9% | 699.0% |
| Revenue growth a year, last 5 years | −18.4% | — |
| Gross margin | 100.0% | — |
| Operating margin | −253.7% | −338.7% |
| Net margin | −297.1% | −325.3% |
| Free cash flow | −$209M | −$181M |
| Free cash flow margin | −377.8% | −288.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 23.1% | 27.1% |
| Last close | $37.27 | $3.99 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $2.4 million | — |
| Piotroski F-score | 2 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Nektar TherapeuticsNuvation Bio
Operating margin
Percent of revenue
Nektar TherapeuticsNuvation Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Nektar TherapeuticsNuvation Bio
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nektar Therapeutics and Nuvation Bio pages.